Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTR003 PET imaging in left ventricular dysfunction and CTO
CTR20213069Phase 2Completed
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Jan 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XTR003 in coronary arteriosclerosis, myocardial infarction (MI), left ventricular systolic dysfunction (LVSD), Chronic total occlusion of the coronary artery (CTO), sponsored by Sinotau Pharmaceutical Group. Started Jan 2022; status: completed.
02
Drugs
XTR003
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)left ventricular systolic dysfunction (LVSD)Chronic total occlusion of the coronary artery (CTO)
Beyond the preview
Go deeper on CTR20213069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213069.